{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:00:50Z","timestamp":1793037650555,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.clon.2022.06.003","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T23:35:56Z","timestamp":1657150556000},"page":"e451-e462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre"],"prefix":"10.1016","volume":"34","author":[{"given":"M.","family":"Suryavanshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Jaipuria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mattoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Dhandha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Khatri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2022.06.003_bib1","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clon.2022.06.003_bib2","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2022.06.003_bib3","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2022.06.003_bib4","doi-asserted-by":"crossref","first-page":"6535","DOI":"10.2147\/OTT.S198945","article-title":"Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer","volume":"12","author":"Wang","year":"2019","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.clon.2022.06.003_bib5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR -mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2022.06.003_bib6","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1158\/1078-0432.CCR-13-1610","article-title":"Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies","volume":"20","author":"Lovly","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.clon.2022.06.003_bib7","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nrc2947","article-title":"Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer","volume":"10","author":"Pao","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clon.2022.06.003_bib8","doi-asserted-by":"crossref","first-page":"9479","DOI":"10.1158\/0008-5472.CAN-08-1643","article-title":"Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations","volume":"68","author":"Yano","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.clon.2022.06.003_bib9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A\u00a0chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.clon.2022.06.003_bib10","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1158\/1078-0432.CCR-13-2233","article-title":"The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial","volume":"20","author":"Costa","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2022.06.003_bib11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2009.11.022","article-title":"Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC","volume":"17","author":"Turke","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clon.2022.06.003_bib12","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(15)00246-6","article-title":"Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer","volume":"16","author":"Tan","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2022.06.003_bib13","first-page":"18","article-title":"Case report: Primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation","volume":"1070","author":"Zheng","year":"2018","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.clon.2022.06.003_bib14","doi-asserted-by":"crossref","first-page":"384","DOI":"10.4103\/lungindia.lungindia_472_17","article-title":"The detection of primary and secondary EGFR mutations using droplet digital PCR in patients with nonsmall cell lung cancer","volume":"35","author":"Suryavanshi","year":"2018","journal-title":"Lung India"},{"issue":"7","key":"10.1016\/j.clon.2022.06.003_bib15","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2022.06.003_bib16","doi-asserted-by":"crossref","first-page":"6494","DOI":"10.1158\/1078-0432.CCR-06-1570","article-title":"Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors","volume":"12","author":"Balak","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2022.06.003_bib17","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-08-0151","article-title":"Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma","volume":"14","author":"Bean","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2022.06.003_bib18","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2007.14.9039","article-title":"Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations","volume":"26","author":"Costa","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.clon.2022.06.003_bib19","first-page":"67","article-title":"Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations \u2013 a review","volume":"4","author":"Stewart","year":"2015","journal-title":"Transl Lung Cancer Res"},{"issue":"Suppl. 8","key":"10.1016\/j.clon.2022.06.003_bib20","article-title":"Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study","volume":"29","author":"Papadimitrakopoulou","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2022.06.003_bib21","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clon.2022.06.003_bib22","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1093\/bioinformatics\/bty897","article-title":"VarSome: the human genomic variant search engine","volume":"35","author":"Kopanos","year":"2018","journal-title":"Bioinformatics"},{"key":"10.1016\/j.clon.2022.06.003_bib23","doi-asserted-by":"crossref","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","article-title":"ClinVar: improving access to variant interpretations and supporting evidence","volume":"46","author":"Landrum","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.clon.2022.06.003_bib24","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.molmed.2018.12.009","article-title":"Principles of resistance to targeted cancer therapy: lessons from basic and translational cancer biology","volume":"25","author":"Sabnis","year":"2019","journal-title":"Trends Mol Med"},{"issue":"2","key":"10.1016\/j.clon.2022.06.003_bib25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JTO.0b013e3182779d18","article-title":"Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions","volume":"8","author":"Oxnard","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"issue":"1","key":"10.1016\/j.clon.2022.06.003_bib26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1470-2045(11)70129-2","article-title":"EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications","volume":"13","author":"Yasuda","year":"2012","journal-title":"Lancet Oncol"},{"issue":"216","key":"10.1016\/j.clon.2022.06.003_bib27","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1126\/scitranslmed.3007205","article-title":"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer","volume":"5","author":"Yasuda","year":"2013","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.clon.2022.06.003_bib28","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41591-018-0007-9","article-title":"Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer","volume":"24","author":"Robichaux","year":"2018","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.clon.2022.06.003_bib29","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1158\/1535-7163.MCT-12-0620","article-title":"EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics","volume":"12","author":"Arcila","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clon.2022.06.003_bib30","first-page":"301","article-title":"Tackling drug resistance in EGFR exon 20 insertion mutant lung cancer","volume":"14","author":"Pacini","year":"2021","journal-title":"Pharmgenom Pers Med"},{"key":"10.1016\/j.clon.2022.06.003_bib31","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/annonc\/mdy336","article-title":"Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions","volume":"29","author":"Piotrowska","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.clon.2022.06.003_bib32","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1158\/2159-8290.CD-20-1683","article-title":"Mobocertinib (TAK-788): a targeted inhibitor of EGFR exon 20 insertion mutants in non-small cell lung cancer","volume":"11","author":"Gonzalvez","year":"2021","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.clon.2022.06.003_bib33","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1158\/1078-0432.CCR-10-3408","article-title":"Effectiveness of tyrosine kinase inhibitors on \"uncommon\" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer","volume":"17","author":"Wu","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.clon.2022.06.003_bib34","doi-asserted-by":"crossref","first-page":"302","DOI":"10.21037\/tlcr.2019.04.12","article-title":"Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment","volume":"8","author":"Zhang","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.clon.2022.06.003_bib35","doi-asserted-by":"crossref","first-page":"20932","DOI":"10.1073\/pnas.0710370104","article-title":"MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib","volume":"104","author":"Bean","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clon.2022.06.003_bib36","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1177\/1758834011422556","article-title":"An overview of the c-MET signaling pathway","volume":"3","author":"Organ","year":"2011","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"10.1016\/j.clon.2022.06.003_bib37","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000457801","article-title":"MET amplification and response to MET inhibitors in stage IV lung adenocarcinoma","volume":"40","author":"Suryavanshi","year":"2017","journal-title":"Oncol Res Treat"},{"issue":"2","key":"10.1016\/j.clon.2022.06.003_bib38","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/annonc\/mdt573","article-title":"Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing","volume":"25","author":"Yu","year":"2014","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.clon.2022.06.003_bib39","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1158\/0008-5472.CAN-08-4055","article-title":"PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR","volume":"69","author":"Sos","year":"2009","journal-title":"Cancer Res"},{"issue":"29","key":"10.1016\/j.clon.2022.06.003_bib40","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1038\/onc.2008.40","article-title":"Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells","volume":"27","author":"Horn","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.clon.2022.06.003_bib41","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.lungcan.2018.07.039","article-title":"Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas","volume":"124","author":"Jin","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clon.2022.06.003_bib42","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s10020-020-00193-z","article-title":"Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC","volume":"26","author":"Sun","year":"2020","journal-title":"Mol Med"},{"issue":"10","key":"10.1016\/j.clon.2022.06.003_bib43","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1634\/theoncologist.2015-0073","volume":"20","author":"Heigener","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.clon.2022.06.003_bib44","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1158\/1078-0432.CCR-10-2571","article-title":"New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer","volume":"17","author":"Oxnard","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2022.06.003_bib45","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1158\/1078-0432.CCR-09-1204","article-title":"Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFRT790M mutant lung cancer","volume":"16","author":"Yamada","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2022.06.003_bib46","article-title":"Acquired MET exon 14 alteration drives secondary resistance to epidermal growth factor receptor tyrosine kinase inhibitor in EGFR-mutated lung cancer","volume":"3","author":"Suzawa","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.clon.2022.06.003_bib47","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/1759-7714.12927","article-title":"Overcoming T790M mutant small cell lung cancer with the third-generation EGFR-TKI osimertinib","volume":"10","author":"Tang","year":"2019","journal-title":"Thorac Cancer"},{"issue":"1","key":"10.1016\/j.clon.2022.06.003_bib48","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lungcan.2013.10.003","article-title":"Loss of an EGFR-amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells","volume":"83","author":"Furugaki","year":"2014","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.clon.2022.06.003_bib49","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clon.2022.06.003_bib50","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-17-2310","article-title":"Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients","volume":"24","author":"Yang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2022.06.003_bib51","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.21037\/jtd.2018.07.61","volume":"10","author":"Jiang","year":"2018","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.clon.2022.06.003_bib52","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/j.jtho.2017.02.023","article-title":"Subclonal therapy by two EGFR TKIs guided by sequential plasma cell-free DNA in EGFR-mutated lung cancer","volume":"12","author":"Peled","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clon.2022.06.003_bib53","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.3747\/co.25.3796","article-title":"Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials","volume":"25","author":"O\u2019Kane","year":"2018","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clon.2022.06.003_bib54","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1158\/1078-0432.CCR-18-1542","article-title":"Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC","volume":"24","author":"Le","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2022.06.003_bib55","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1158\/2159-8290.CD-18-1022","article-title":"Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion","volume":"8","author":"Piotrowska","year":"2018","journal-title":"Cancer Disco"},{"key":"10.1016\/j.clon.2022.06.003_bib56","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jtho.2018.05.027","article-title":"Receptor tyrosine kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors","volume":"13","author":"Schrock","year":"2018","journal-title":"J\u00a0Thorac Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655522002758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655522002758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:52:36Z","timestamp":1760543556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655522002758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0936655522002758"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2022.06.003","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2022.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}